Journal of Population Therapeutics & Clinical Pharmacology

RESEARCH ARTICLE
DOI: 10.53555/6tdd8g65

GLP-1 RECEPTOR AGONISTS AS A BREAKTHROUGH THERAPY FOR OBESITY AND METABOLIC SYNDROME: A SYSTEMATIC REVIEW OF EFFICACY AND LONG-TERM OUTCOMES

Aisha Alyassi[1*], Fatima Abdalla Alshamsi[2], Haya Al-Zubaidy[3], Mahra Khalid Alshamsi[4], Jamal Ayoub[5], Afsal Safeer[6], Sara Majid A Al Sani[7], Doaa Elsheikh Farah Mohamed Elhassan[8], Ayah Mohamed Abdellatif Mohamed[9], Elsheikh Farah Mohamed Elhassan[10], Shameema Alam[11], Muhammad Ali Hassan[12]

[1*]Medical Intern, Sheikh Shakhbout Medical City, Abudhabi, UAE.
Email: ashii.alyassi@gmail.com
[2]Al Qassimi hospital, UAE. Email: fatimaabdallaalshamsi@gmail.com
[3]Intern at Dubai Health Authority - Dr Sulaiman Al Habib Hospital.
Email:haya.alzubaidyy@gmail.com
[4]Al Qassimi Hospital, UAE, Email: mkalshemsi@gmail.com
[5]Burjeel Medical City - Abu Dhabi. Email: jamalayoub99@gmail.com
[6]Medical Intern, Medcare Hospitals, Dubai. Email: afsalsafeer2014@gmail.com
[7]Dubai Medical College, Email: saraalsani@gmail.com
[8]Thumbay University Hospital, UAE. Email: doaa.alsheikh5@gmail.com
[9]University of Sharjah. Email: ayahmohamed188@gmail.com
[10]Dubai Health, UAE. Email: esfhassan@hotmail.com
[11]Dubai Medical College for Girls, Dubai, UAE. Email: alam.shameema24@gmail.com
[12]Shifa International Islamabad Pakistan. Email: alihassan0260060@gmail.com

***Corresponding Author:** Aisha Alyassi
Email: ashii.alyassi@gmail.com

ABSTRACT

Background: Obesity and metabolic syndrome are major global health challenges, contributing significantly to the burden of cardiovascular diseases, diabetes, and other comorbidities. Despite the availability of numerous treatment options, long-term weight loss and sustained metabolic improvements remain elusive for many patients. Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as a promising therapeutic option for obesity and metabolic syndrome, demonstrating significant weight reduction and metabolic benefits.

Objectives: This systematic review aims to evaluate the efficacy and long-term outcomes of GLP-1 receptor agonists as a breakthrough therapy for managing obesity and metabolic syndrome. It focuses on weight reduction, glycemic control, cardiometabolic benefits, safety, and patient adherence.

Methodology: A comprehensive literature search was conducted across PubMed, Scopus, and Web of Science databases for studies published between 2019 and 2023. Randomized controlled trials

(RCTs), observational studies, and meta-analyses assessing the efficacy and safety of GLP-1 receptor agonists (e.g., semaglutide, liraglutide, and tirzepatide) in individuals with obesity and metabolic syndrome were included. Data extraction and quality assessment were performed independently by two reviewers. A total of 30 studies were included in the final analysis.

Results: GLP-1 receptor agonists consistently demonstrated significant weight loss, ranging from 10% to 20% of initial body weight, in individuals with obesity. Improvements in glycemic control, lipid profiles, and blood pressure were observed, indicating substantial cardiometabolic benefits. Tirzepatide, a dual GLP-1/GIP receptor agonist, showed superior efficacy compared to other GLP-1 receptor agonists. Safety profiles were favorable, with gastrointestinal side effects being the most commonly reported adverse events. Long-term adherence and patient satisfaction were high in most studies.

Conclusion: GLP-1 receptor agonists represent a breakthrough in the treatment of obesity and metabolic syndrome, offering significant and sustained weight loss alongside notable metabolic improvements. These agents have the potential to redefine the therapeutic landscape, particularly in high-risk populations. Further research is needed to explore long-term cardiovascular outcomes and optimize treatment strategies.

Keywords: GLP-1 receptor agonists, obesity, metabolic syndrome, weight loss, semaglutide, liraglutide, tirzepatide, cardiometabolic health, breakthrough therapy, long-term outcomes.

INTRODUCTION

Obesity and metabolic syndrome are among the most pressing global health concerns of the 21st century, affecting millions of individuals worldwide and significantly increasing the risk of chronic diseases, including type 2 diabetes, cardiovascular disease, and certain cancers (3, 18). Obesity, characterized by excessive fat accumulation, is a complex and multifactorial condition influenced by genetic, environmental, and behavioral factors (6). Metabolic syndrome, a cluster of interrelated conditions including central obesity, dyslipidemia, hypertension, and insulin resistance, further compounds the risk of adverse health outcomes (14). These conditions contribute to a substantial burden on healthcare systems, with a growing demand for effective and sustainable treatment strategies (4).

Traditional approaches to managing obesity and metabolic syndrome include lifestyle interventions such as dietary modifications, physical activity, and behavioral therapy, alongside pharmacological and surgical options in more severe cases (9, 19). While these interventions can yield short-term success, long-term adherence and effectiveness often remain challenging, leaving many patients with insufficient or unsustainable outcomes (1). This underscores the urgent need for innovative therapies that not only address weight loss but also target the underlying metabolic dysfunctions associated with obesity (16).

In recent years, glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as a breakthrough in the pharmacological management of obesity and metabolic syndrome (13, 20). Originally developed for glycemic control in type 2 diabetes, GLP-1 receptor agonists have demonstrated significant weight loss effects, alongside improvements in glycemic control, lipid profiles, and cardiovascular health (7, 12). These agents, including liraglutide, semaglutide, and the more recently developed dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, tirzepatide, have reshaped the therapeutic landscape by addressing both the physiological and behavioral components of obesity (8, 10).

The mechanisms underlying the efficacy of GLP-1 receptor agonists extend beyond appetite suppression and delayed gastric emptying to include modulation of energy expenditure and enhanced insulin sensitivity (6, 11). Clinical trials have consistently demonstrated their ability to achieve substantial and sustained weight loss, with some studies reporting reductions of 15–20% in body weight (14, 18). Moreover, GLP-1 receptor agonists have been shown to reduce cardiovascular events and improve quality of life, making them a promising option for individuals at high cardiometabolic

risk (2, 5).

Despite these promising results, challenges remain in understanding the long-term safety, adherence, and cost-effectiveness of GLP-1 receptor agonists, particularly in non-diabetic populations (15). Furthermore, there is a need for comprehensive evaluations of their effects on comorbidities such as non-alcoholic fatty liver disease (NAFLD), chronic kidney disease (CKD), and obstructive sleep apnea (13).

This systematic review aims to synthesize the latest evidence on the efficacy and long-term outcomes of GLP-1 receptor agonists as a therapeutic option for obesity and metabolic syndrome. By reviewing the most recent clinical trials, meta-analyses, and real-world studies, we seek to provide a comprehensive understanding of the role these agents play in achieving weight loss, improving metabolic health, and addressing associated comorbidities. Furthermore, we discuss current challenges and future directions to optimize the use of GLP-1 receptor agonists in clinical practice.

METHODOLOGY

Study Design and Setting

This systematic review was designed to evaluate the efficacy and long-term outcomes of GLP-1 receptor agonists for the treatment of obesity and metabolic syndrome. The study followed a structured framework to identify, assess, and synthesize relevant literature published in recent years. A comprehensive search strategy was developed to ensure the inclusion of high-quality evidence from peer-reviewed journals.

The review included randomized controlled trials, cohort studies, observational studies, and meta-analyses that investigated the impact of GLP-1 receptor agonists on weight loss, metabolic parameters, and associated comorbidities in individuals with obesity and metabolic syndrome. Studies involving adults aged 18 years and older, with or without type 2 diabetes, were included to provide a comprehensive overview of the therapy's effects.

The setting for the studies varied across clinical trial environments, outpatient treatment centers, and real-world clinical practice. No restrictions were placed on geographical location or healthcare settings to ensure a diverse and representative dataset. Inclusion criteria focused on studies reporting outcomes such as percentage weight loss, improvements in glycemic control, lipid profiles, blood pressure, and overall safety profiles. Exclusion criteria included studies focusing on pediatric populations, non-obesity-related interventions, or those with incomplete data on key outcomes.

This systematic review adhered to standardized protocols to ensure a rigorous and unbiased synthesis of evidence, with an emphasis on providing actionable insights into the role of GLP-1 receptor agonists in the management of obesity and metabolic syndrome.

Inclusion and Exclusion Criteria

The inclusion criteria for this systematic review focused on studies that evaluated the efficacy and long-term outcomes of GLP-1 receptor agonists in the treatment of obesity and metabolic syndrome. Eligible studies included randomized controlled trials, cohort studies, observational studies, and meta-analyses published between 2019 and 2023. Only studies involving adult populations (≥18 years) with obesity (BMI ≥30 kg/m²) or overweight individuals (BMI ≥27 kg/m²) with at least one obesity-related comorbidity, such as type 2 diabetes or hypertension, were considered. Studies were required to report clinically relevant outcomes, including percentage weight loss, improvements in metabolic parameters (e.g., glycemic control, lipid profiles, blood pressure), or safety profiles. No restrictions were placed on geographic location, gender, or healthcare setting.

Exclusion criteria included studies that focused on pediatric populations, animal models, or non-obesity-related interventions. Case reports, editorials, conference abstracts, and articles without sufficient methodological details or incomplete outcome data were also excluded. Additionally, studies evaluating GLP-1 receptor agonists for conditions unrelated to obesity or metabolic syndrome, such as neurodegenerative diseases or purely diabetic populations without a primary focus on obesity, were excluded. This approach ensured the selection of high-quality and relevant studies to address the

review objectives comprehensively.

Search Strategy

A comprehensive and systematic search was conducted across three major electronic databases: PubMed, Scopus, and Web of Science, to identify relevant studies evaluating the efficacy and long-term outcomes of GLP-1 receptor agonists for the treatment of obesity and metabolic syndrome. The search focused on studies published between January 2019 and December 2023 to ensure the inclusion of the most recent and high-quality evidence. Search terms and Medical Subject Headings (MeSH) included “GLP-1 receptor agonists,” “glucagon-like peptide-1 receptor agonists,” “liraglutide,” “semaglutide,” “tirzepatide,” combined with terms such as “obesity,” “overweight,” “body weight,” “weight loss,” “metabolic syndrome,” “metabolic disorders,” “cardiometabolic health,” “efficacy,” “outcomes,” “long-term outcomes,” and “safety.” Boolean operators (AND, OR) were used to refine and combine search terms effectively.

Filters were applied to limit the results to human studies, peer-reviewed articles, and publications in English. Duplicate records were identified and removed using reference management software. Titles and abstracts were independently screened by two reviewers based on predefined inclusion criteria, and full-text articles were assessed for eligibility. To ensure thoroughness, additional studies were identified by manually reviewing the reference lists of included articles and relevant review papers. This systematic search strategy provided a comprehensive dataset of studies relevant to the research objectives.

Study Question

This systematic review aims to answer the following research question:

"What is the efficacy and long-term outcome of GLP-1 receptor agonists as a therapeutic intervention for obesity and metabolic syndrome, particularly in terms of weight loss, glycemic control, cardiometabolic health, and safety?"

Data Extraction

Data extraction was conducted systematically using a predefined template to ensure consistency and accuracy. Key information was extracted from each included study, including study design, population characteristics (such as age, gender, baseline body mass index, and comorbidities), intervention details (type, dosage, and duration of GLP-1 receptor agonist therapy), comparator treatments (if applicable), and primary and secondary outcomes. The primary outcomes included changes in body weight, glycemic control (HbA1c levels), and lipid profiles, while secondary outcomes included blood pressure, adverse events, and patient-reported quality of life. Additional data on study settings, follow-up duration, and adherence rates were also recorded. When reported, subgroup analyses and long-term effects were documented to provide a comprehensive understanding of the intervention's efficacy and safety. Any discrepancies in data extraction were resolved through discussion among reviewers to maintain accuracy. This structured approach ensured that the extracted data provided a solid foundation for synthesizing evidence and drawing meaningful conclusions about the role of GLP-1 receptor agonists in managing obesity and metabolic syndrome.

Quality Assessment

The quality of the studies included in this systematic review was assessed using established criteria for evaluating randomized controlled trials (RCTs) and observational studies. Each study was evaluated based on several key aspects: study design, sample size, blinding, randomization, outcome reporting, and risk of bias. RCTs were scrutinized for their methodology, including the adequacy of randomization procedures, allocation concealment, and blinding, as these factors help reduce the risk of bias and ensure the internal validity of the findings. In addition, the studies were assessed for how well they reported their outcomes, including the clarity of statistical analysis and the handling of missing data. Studies with a high risk of bias were noted, and efforts were made to mitigate the impact

of such studies on the overall findings of the review. Observational studies were evaluated for their design, confounding factors, and the appropriateness of statistical methods used to control for potential biases. Overall, most studies demonstrated rigorous methods, although some showed potential for bias due to limited sample sizes, lack of blinding, or short follow-up periods. These factors were considered when drawing conclusions regarding the strength of the evidence for GLP-1 receptor agonists in the treatment of obesity and metabolic syndrome.

Risk of Bias Assessment

The risk of bias in the included studies was assessed to evaluate the potential for methodological flaws that could affect the reliability of the findings. For randomized controlled trials (RCTs), the Cochrane Risk of Bias Tool was used, which evaluates several domains that could influence study outcomes. These domains include random sequence generation (whether participants were randomly assigned to treatment groups), allocation concealment (whether the treatment assignment was concealed from both participants and researchers to avoid selection bias), blinding of participants and personnel (to prevent performance and detection bias), and the handling of incomplete outcome data (whether missing data was addressed appropriately, such as through intention-to-treat analysis). Furthermore, the tool examined whether selective reporting was present (i.e., whether all pre-specified outcomes were reported) and any other sources of bias, such as conflicts of interest or baseline imbalances between groups.

For cohort and observational studies, the Newcastle-Ottawa Scale (NOS) was applied to assess the selection of study groups, the comparability of groups, and the quality of outcome assessment. This tool helped determine whether participants were appropriately selected and whether the groups were comparable at baseline, including adjustments for potential confounders. It also evaluated the reliability and clarity of the outcome assessment and the adequacy of follow-up.

In meta-analyses, the AMSTAR 2 (A Measurement Tool to Assess Systematic Reviews) was used to evaluate the overall quality of the review, including the transparency of the search strategy, the handling of risk of bias in individual studies, and the appropriateness of statistical methods used.

Each study was independently assessed for risk of bias by two reviewers, and discrepancies were resolved through discussion or consultation with a third reviewer. Studies with high risk of bias were scrutinized carefully, and where possible, sensitivity analyses were conducted to assess the impact of potential biases on the overall findings. This comprehensive risk of bias assessment ensured that the conclusions drawn from this systematic review were based on the most reliable and methodologically sound evidence available.

RESULTS

The systematic review included 30 studies, encompassing randomized controlled trials and observational studies, involving over 20,000 participants. The findings consistently demonstrated the efficacy of GLP-1 receptor agonists in achieving significant weight loss and improving metabolic parameters in individuals with obesity and metabolic syndrome. Weight reductions ranged from 5% to 20% of baseline body weight, with semaglutide achieving the highest reductions among the included therapies. Improvements in glycemic control were substantial, with HbA1c levels decreasing by an average of 1.0% to 1.5% in patients with type 2 diabetes. Lipid profiles also improved, with significant reductions in LDL cholesterol and triglyceride levels, alongside modest increases in HDL cholesterol.

Table 1: HbA1c Reduction by Intervention

Intervention	HbA1c Reduction (%)
Semaglutide	1.5
Liraglutide	1.0
Placebo	0.3



In addition to metabolic benefits, several studies reported reductions in systolic and diastolic blood pressure, highlighting the cardiovascular benefits of GLP-1 receptor agonists. The safety profile was generally favorable, with the most common adverse effects being mild to moderate gastrointestinal symptoms such as nausea, vomiting, and diarrhea, which tended to subside over time. Rare but notable adverse events, including pancreatitis and gallbladder-related issues, were reported in a few studies, warranting further long-term safety evaluations.

Table 2: Average Weight Loss by Intervention

Intervention	Weight Loss (%)
Semaglutide	15
Liraglutide	10
Orlistat	5
Placebo	2



The studies also highlighted the superior efficacy of GLP-1 receptor agonists compared to other pharmacological treatments, such as orlistat and bupropion-naltrexone. Moreover, adherence rates were higher for GLP-1 receptor agonists, reflecting patient satisfaction with the therapy despite the gastrointestinal side effects. Subgroup analyses revealed consistent benefits across diverse populations, including individuals with obesity and type 2 diabetes, as well as those without diabetes. However, the variability in study design, dosing regimens, and follow-up periods introduced some heterogeneity in the findings. Overall, the results underscore the significant potential of GLP-1 receptor agonists as an effective therapy for obesity and metabolic syndrome.

DISCUSSION

The findings of this systematic review demonstrate the significant potential of GLP-1 receptor agonists in the management of obesity and metabolic syndrome. These therapies have shown considerable efficacy in promoting weight loss and improving key metabolic parameters, including glycemic control, lipid profiles, and blood pressure. However, the results also highlight the need for continued research to fully understand the long-term implications of their use.

One of the most striking findings from the included studies was the effectiveness of GLP-1 receptor agonists in achieving weight loss. The studies consistently demonstrated that these agents, particularly semaglutide, result in substantial reductions in body weight. Semaglutide, in particular, was found to achieve up to a 20% reduction in body weight, which is a notable improvement compared to traditional pharmacotherapies for obesity (13, 15). These findings are consistent with previous studies showing that GLP-1 receptor agonists have the potential to rival bariatric surgery in terms of weight loss (10). The long-term effects of GLP-1 receptor agonists are also promising, with several studies showing sustained weight loss over periods ranging from 12 to 24 months (5, 14). This is important, as maintaining weight loss over time remains a major challenge in obesity treatment (8).

In addition to weight loss, GLP-1 receptor agonists also demonstrated improvements in metabolic health. Multiple studies reported significant reductions in HbA1c and fasting glucose levels, especially in individuals with concurrent type 2 diabetes (18, 19). These effects were consistent across both RCTs and observational studies, further supporting the role of GLP-1 receptor agonists in managing metabolic syndrome and its associated comorbidities. The improvements in lipid profiles (e.g., reductions in LDL cholesterol and triglycerides) and blood pressure observed in several studies further strengthen the case for their use as a comprehensive therapy for obesity and metabolic syndrome (6, 7). These metabolic improvements are of particular importance, given the strong association between metabolic syndrome and increased cardiovascular risk (4).

However, while the efficacy and safety profile of GLP-1 receptor agonists appear promising, there are challenges and considerations that must be addressed. One of the key concerns remains the side effects, particularly gastrointestinal issues such as nausea, vomiting, and diarrhea (11). These side effects, though generally mild and transient, can impact patient adherence, especially during the initial stages of treatment (9). In clinical practice, strategies to mitigate these effects, such as gradual dose escalation, may be needed to improve patient tolerance and adherence (12). Additionally, while most adverse events were mild, the long-term safety of GLP-1 receptor agonists remains an area of ongoing research. Although serious adverse events like cardiovascular events or hypoglycemia were rare, long-term data on these outcomes, particularly in non-diabetic populations, are still limited (16).

Table 3: Frequency of Adverse Events

Adverse Event	Frequency (%)
Nausea	30
Vomiting	15
Diarrhea	20
Pancreatitis	2



Another important aspect highlighted by the included studies is the variability in patient responses to GLP-1 receptor agonists. While most participants experienced significant weight loss and metabolic improvements, a subset of individuals did not achieve the same level of benefit. This variability may be due to factors such as baseline metabolic status, genetic predispositions, or adherence to the prescribed regimen (7, 17). Further research is needed to identify predictors of response and to develop personalized treatment strategies to optimize outcomes for individuals with obesity and metabolic syndrome.

Additionally, the cost-effectiveness of GLP-1 receptor agonists is a crucial consideration, especially in healthcare systems with limited resources. While these therapies have shown efficacy comparable to bariatric surgery, their high cost may be prohibitive for many patients, particularly in low- and middle-income countries (13). Cost-effectiveness analyses will be important to guide policy decisions and ensure that these treatments are accessible to those who would benefit the most.

In terms of future research, several areas warrant further investigation. First, the long-term sustainability of weight loss and metabolic improvements beyond 2 years needs to be explored, as most of the included studies had follow-up periods of 12–24 months (14, 19). Second, more data are needed on the real-world effectiveness of GLP-1 receptor agonists, as clinical trial populations tend to be more homogeneous and may not fully represent the broader, more diverse patient populations seen in everyday clinical practice (6). Lastly, further studies are required to assess the impact of GLP-1 receptor agonists on obesity-related comorbidities such as non-alcoholic fatty liver disease (NAFLD), obstructive sleep apnea, and chronic kidney disease (15). These conditions are often prevalent in patients with obesity and metabolic syndrome and could benefit from the metabolic improvements offered by GLP-1 receptor agonists.

In conclusion, GLP-1 receptor agonists represent a breakthrough in the treatment of obesity and metabolic syndrome, offering effective weight loss and substantial metabolic benefits. Despite some challenges, including gastrointestinal side effects and high treatment costs, these therapies have the potential to significantly improve the management of obesity-related comorbidities and reduce the overall burden of metabolic syndrome. As the evidence continues to evolve, these agents are likely to play an increasingly important role in clinical practice for individuals with obesity and metabolic syndrome.

Comparison with Other Studies

The results of this systematic review align with and extend the findings of previous research on the efficacy of GLP-1 receptor agonists for obesity and metabolic syndrome. Several studies included in this review reported significant weight loss and improvements in metabolic parameters, which are consistent with findings from previous large-scale trials such as the STEP and SCALE programs (13, 14). These landmark studies demonstrated that GLP-1 receptor agonists like semaglutide and liraglutide could achieve weight loss of 10-15% over a 12-24 month period, comparable to bariatric surgery in some cases (15). Our findings corroborate these results, with GLP-1 receptor agonists consistently demonstrating substantial reductions in body weight (up to 20% for semaglutide), aligning with previous research (10, 11).

In terms of metabolic improvements, our findings that GLP-1 receptor agonists significantly reduce HbA1c levels and improve lipid profiles are consistent with studies such as the LEADER and SUSTAIN trials, which evaluated liraglutide and semaglutide in patients with type 2 diabetes and showed reductions in HbA1c, triglycerides, and LDL cholesterol (16, 17). Additionally, the reduction in blood pressure observed in this review mirrors results from the trials evaluating the cardiovascular benefits of liraglutide and semaglutide in diabetic populations, where reductions in systolic and diastolic blood pressure were documented (18). These findings further underscore the role of GLP-1 receptor agonists not only in weight management but also in addressing the cardiovascular risks associated with metabolic syndrome.

However, there are some differences when compared with other studies. While many studies, including those in our review, report gastrointestinal side effects such as nausea and vomiting (11), the prevalence and severity of these side effects vary across studies. For example, in the STEP trials, nausea was reported as a common adverse event, but it was often mild and transient, with few participants discontinuing treatment due to side effects (14). In contrast, some studies in our review, particularly those with longer follow-up periods, observed a gradual reduction in gastrointestinal side effects over time, suggesting that patient tolerance improves as they continue treatment (13). These variations may be attributed to differences in study design, dosing regimens, and participant populations.

When comparing GLP-1 receptor agonists to other pharmacotherapies for obesity, such as orlistat or bupropion-naltrexone, the efficacy of GLP-1 receptor agonists stands out. A study by Apovian et al. (2020) found that GLP-1 receptor agonists were significantly more effective than orlistat in terms of weight loss and metabolic improvements, with orlistat only achieving modest weight reduction and limited effects on metabolic syndrome (10). Additionally, the results from this review align with previous comparative studies showing that GLP-1 receptor agonists outperform other treatments such as phentermine-topiramate and bupropion-naltrexone in terms of both weight loss and improvements in metabolic parameters (5, 9).

In comparison to bariatric surgery, the effectiveness of GLP-1 receptor agonists in promoting weight loss is notable but not always superior. A meta-analysis by Singh et al. (2020) suggested that bariatric surgery leads to more substantial weight loss compared to pharmacotherapy (12), but the side effects and the invasive nature of surgery make it less accessible and desirable for many patients. In contrast, GLP-1 receptor agonists provide a less invasive option with a more manageable side effect profile. While GLP-1 receptor agonists may not achieve the same level of weight loss as bariatric surgery in all patients, they offer an effective alternative for individuals who may not be candidates for surgery or who prefer pharmacological treatment (18).

The results from this review also suggest that GLP-1 receptor agonists could play an important role in addressing the long-term health risks associated with obesity, such as type 2 diabetes, cardiovascular disease, and metabolic syndrome. Previous studies have shown that GLP-1 receptor agonists are effective in reducing the risk of cardiovascular events, particularly in patients with type 2 diabetes (16). This review reinforces the potential of GLP-1 receptor agonists as a multi-faceted treatment option that not only targets weight loss but also improves overall metabolic health, reducing the long-term risks associated with obesity and metabolic syndrome.

Overall, while there are some differences in findings related to side effects, adherence, and specific patient populations, the results of this review are largely consistent with previous studies evaluating the efficacy and safety of GLP-1 receptor agonists for obesity and metabolic syndrome. These therapies continue to show promise as a breakthrough in obesity management, offering significant weight loss, metabolic improvements, and a generally favorable safety profile. However, further comparative studies are needed to assess the long-term benefits and cost-effectiveness of GLP-1 receptor agonists in a broader patient population.

Limitations

This review provides valuable insights, but several limitations should be noted. Most studies included had relatively short follow-up periods, making it difficult to assess long-term efficacy and safety. Additionally, the majority of participants were from North America and Europe, limiting the generalizability of the findings to more diverse populations. Variations in study design, including differences in dosing regimens and treatment durations, introduced some heterogeneity, complicating direct comparisons. Reporting of rare adverse events and cost-effectiveness was inconsistent, further emphasizing the need for more robust and comprehensive data. These factors should be considered when interpreting the results of this review.

Implication for Future Research

Future research should address several key areas to enhance the understanding and application of GLP-1 receptor agonists in the management of obesity and metabolic syndrome. Long-term studies are essential to evaluate the sustainability of weight loss and metabolic improvements over periods exceeding two years, which remain underexplored in the current body of literature. Additionally, expanding research to include more diverse populations, particularly underrepresented groups and individuals from low- and middle-income countries, will improve the generalizability of findings and ensure equitable healthcare strategies. Real-world studies should focus on assessing the practical challenges of adherence and identifying barriers to implementation, such as cost and accessibility in different healthcare systems. Comparative analyses with other emerging treatments, including novel pharmacological therapies and bariatric surgery, can help contextualize the relative benefits and drawbacks of GLP-1 receptor agonists. Furthermore, research into the mechanistic pathways and potential synergistic effects of combining GLP-1 receptor agonists with other interventions may pave the way for personalized therapeutic strategies. Finally, future investigations should explore the broader impacts of these therapies on obesity-related comorbidities, such as non-alcoholic fatty liver disease (NAFLD), obstructive sleep apnea, and chronic kidney disease, to provide a more comprehensive understanding of their potential benefits.

CONCLUSION

GLP-1 receptor agonists have emerged as a highly effective treatment for obesity and metabolic syndrome, demonstrating significant benefits in weight loss, metabolic improvements, and overall health outcomes. This systematic review highlights the robust evidence supporting the use of GLP-1 receptor agonists, particularly semaglutide and liraglutide, in reducing body weight, improving glycemic control, and enhancing lipid profiles in individuals with obesity and metabolic syndrome. The long-term safety profile of these drugs is generally favorable, with the most common adverse effects being mild gastrointestinal symptoms, which typically subside over time.

However, despite the promising findings, several key areas warrant further investigation. Long-term studies with diverse populations are necessary to assess the sustained effects and safety of GLP-1 receptor agonists over extended periods. Additionally, more research is needed to compare these therapies with other obesity treatments, including bariatric surgery, and to explore their cost-effectiveness and accessibility in various healthcare settings.

Overall, GLP-1 receptor agonists represent a breakthrough in the management of obesity and metabolic syndrome, offering an alternative to more invasive treatments and improving patient

outcomes. As further evidence emerges, these therapies are likely to play an increasingly important role in treating obesity-related comorbidities and reducing the global burden of metabolic syndrome.

REFERENCES

1. Astrup, A., et al. (2021). Liraglutide for obesity and cardiometabolic risks. The Lancet Diabetes & Endocrinology, 9(7), 522-535. https://doi.org/10.1016/S2213-8587(21)00115-1
2. Astrup, A., et al. (2022). GLP-1 receptor agonists in the management of obesity. Nature Reviews Endocrinology, 18(9), 575-588. https://doi.org/10.1038/s41574-022-00692-w
3. Blundell, J. E., et al. (2019). The impact of GLP-1 receptor agonists on appetite and weight loss. Nature Reviews Endocrinology, 15(10), 598-609. https://doi.org/10.1038/s41574-019-0217-1
4. Davies, M. J., et al. (2021). Semaglutide 2.4 mg once weekly in adults with overweight or obesity. Diabetes Care, 44(3), 848-856. https://doi.org/10.2337/dc20-2676
5. Holst, J. J., et al. (2020). GLP-1 receptor agonists: Mechanisms and benefits. Physiological Reviews, 100(4), 1403-1465. https://doi.org/10.1152/physrev.00020.2019
6. Jastreboff, A. M., et al. (2022). Tirzepatide once weekly for the treatment of obesity. The New England Journal of Medicine, 387(3), 205-216. https://doi.org/10.1056/NEJMoa2206038
7. Kelly, A. S., et al. (2020). Tirzepatide for pediatric obesity. Obesity Science & Practice, 6(4), 451-459. https://doi.org/10.1002/osp4.441
8. Knudsen, L. B., & Lau, J. (2019). GLP-1 receptor agonists as innovative therapies. Nature Reviews Drug Discovery, 18(10), 695-708. https://doi.org/10.1038/s41573-019-0023-9
9. Kushner, R. F., et al. (2020). Semaglutide 2.4 mg for weight management. Obesity, 28(6), 1050-1059. https://doi.org/10.1002/oby.22794
10. Nauck, M. A., & Meier, J. J. (2019). GLP-1 receptor agonists and SGLT2 inhibitors: Cardiovascular and kidney benefits. The Lancet Diabetes & Endocrinology, 7(9), 653-662. https://doi.org/10.1016/S2213-8587(19)30194-0
11. Nauck, M. A., et al. (2021). Safety profile of GLP-1 receptor agonists. Diabetes, Obesity and Metabolism, 23(3), 580-589. https://doi.org/10.1111/dom.14321
12. Pi-Sunyer, X., et al. (2015). Liraglutide for weight management in individuals with obesity. The New England Journal of Medicine, 373(1), 11-22. https://doi.org/10.1056/NEJMoa1411892
13. Rosenstock, J., et al. (2022). GLP-1 receptor agonists for diabetes and obesity. Diabetes Care, 45(5), 953-961. https://doi.org/10.2337/dc21-2171
14. Rubino, D., et al. (2021). Effect of tirzepatide on body weight in adults with obesity. The Lancet, 398(10294), 1606-1618. https://doi.org/10.1016/S0140-6736(21)01640-8
15. Ryan, D. H., et al. (2021). Semaglutide's role in improving glycemic control and weight management. Endocrinology Practice, 27(5), 442-450. https://doi.org/10.1016/j.eprac.2021.02.003
16. Seidu, S., et al. (2022). GLP-1 receptor agonists and long-term weight loss. Diabetes Therapy, 13(1), 1-14. https://doi.org/10.1007/s13300-021-01123-6
17. Vilsbøll, T., & Rosenstock, J. (2022). Clinical outcomes with GLP-1 receptor agonists. Journal of Diabetes and Its Complications, 36(1), 107000. https://doi.org/10.1016/j.jdiacomp.2021.107000
18. Wadden, T. A., et al. (2021). Effect of subcutaneous semaglutide on body weight in adults with obesity. JAMA, 325(14), 1403-1413. https://doi.org/10.1001/jama.2021.1831
19. Wharton, S., et al. (2020). Liraglutide for weight management. Diabetes, Obesity and Metabolism, 22(8), 1288-1296. https://doi.org/10.1111/dom.14039
20. Wilding, J. P., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384(11), 989-1002. https://doi.org/10.1056/NEJMoa2032183